Enhancing Influenza Treatment Access: Should Oseltamivir Be OTC?
Overview
Oseltamivir, an antiviral effective against influenza, is being considered for over-the-counter (OTC) availability to improve timely treatment access. Early treatment reduces illness duration and complications, but current prescription requirements contribute to underutilization, especially among high-risk groups.
Background
Influenza causes millions of illnesses and hundreds of thousands of hospitalizations annually in the US, with severe outcomes common in young children, older adults, and those with chronic conditions. Antiviral treatment, particularly with oseltamivir, is most effective when started within 48 hours of symptom onset, reducing symptom duration and complications. Despite guidelines recommending antiviral use for high-risk individuals, underutilization is widespread due to delays in accessing prescriptions. The proposal to make oseltamivir OTC aims to address these barriers and improve public health outcomes.
Data Highlights
Study
Finding
US Influenza Burden
9.3 to 41 million illnesses and 100,000 to 710,000 hospitalizations annually
High-risk Outpatients Seeking Care
41% sought care within 2 days of symptom onset
Antiviral Prescription Rates (2009–2016)
20% of patients with influenza-like illness received antivirals
High-risk Patients Receiving Antivirals
37% received prescriptions within 48 hours
High-risk Children Under 2 Years
Over 40% did not receive guideline-concordant antivirals (2016–2019)
Hospitalized Children Treated with Antivirals
Declined from 70%–86% (2017–2018) to 52%–59% (2022–2023)
Symptom Duration Reduction with Early Oseltamivir
0.83 to 1.05 days reduction when started early
Key Findings
Oseltamivir reduces influenza symptom duration by approximately 0.5 to 1.5 days when started within 48 hours.
Early treatment (within 6–12 hours) yields greater effectiveness.
Antiviral use is underutilized, with only 20% of influenza-like illness patients receiving prescriptions and even lower rates among high-risk groups.
OTC availability could improve timely access, reduce illness duration, and decrease secondary transmission within households.
Improved access is critical during pandemics to reduce healthcare system burden and nosocomial transmission.
Declining antiviral use in hospitalized children highlights the need for better access and adherence to guidelines.
Clinical Implications
Making oseltamivir available OTC could facilitate earlier treatment initiation, especially for high-risk patients who currently face barriers to timely care. This may reduce influenza complications, hospitalizations, and transmission. Clinicians should consider the potential benefits of OTC antivirals alongside rapid diagnostic testing to optimize influenza management.
Conclusion
Expanding access to oseltamivir through OTC availability has the potential to improve influenza outcomes by enabling earlier treatment and reducing transmission. Careful consideration of benefits and risks is warranted to enhance antiviral utilization and public health preparedness.
Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season
